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DOI 10.1016/j.ccr.2011.12.023SUMMARYMedulloblastomas that display a large cell/anaplastic morphology and overexpress the cellular c-MYC gene
are highly aggressive and carry a very poor prognosis. This so-called MYC-subgroup differs in its histopa-
thology, gene expression profile, and clinical behavior from other forms of medulloblastoma. We generated
a mouse model of MYC-subgroup medulloblastoma by transducing Trp53-null cerebellar progenitor cells
with Myc. The cardinal features of these mouse medulloblastomas closely mimic those of human MYC-
subgroup tumors and significantly differ from mouse models of the Sonic-Hedgehog- and WNT-disease
subgroups. This mouse model should significantly accelerate understanding and treatment of the most
aggressive form of medulloblastoma and infers distinct roles for MYC and MYCN in tumorigenesis.INTRODUCTION
Medulloblastoma (MB)—the most common malignant pediatric
brain tumor—includes at least four clinically and molecularly
distinct subgroups (Cho et al., 2011; Kool et al., 2008; Northcott
et al., 2011; Thompson et al., 2006). Sonic Hedgehog (SHH)-
subgroup MB most frequently results from inactivating muta-
tions of PTCH1 (the SHH receptor) or suppressor of fused
(a downstream signal transducer). SHH signaling ultimately
activates GLI family transcription factors that upregulate
pro-proliferative genes, such as MYCN, CCND1, and CCND2
(cyclins D1 and D2), and lead to the reduced expression of
inhibitors of cyclin-dependent kinases (CDKs), including
p27KIP1 and p18INK4c (Roussel and Hatten, 2011). About 50%Significance
MYC-subgroup medulloblastoma (MB) is one of the most agg
combination surgery, radiotherapy, and chemotherapy and k
Mouse models of the Sonic Hedgehog and WNT forms of MB
of these disease subgroups. In contrast, the absence of preclin
this important tumor. Here, we describe the MYC-driven mou
histopathology, and clinical behavior of human MYC-subgrou
to develop therapeutic modalities and determine the origin of
168 Cancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc.of SHH-subgroup MBs exhibit a desmoplastic/nodular
histology and carry an intermediate prognosis in patients who
receive contemporary surgical intervention and chemotherapy
(Cho et al., 2011; Ellison et al., 2011a; Lam et al., 1999; North-
cott et al., 2011; Raffel et al., 1997). In contrast, the WNT-
subgroup disease has an excellent prognosis, exhibits a
‘‘classic’’ morphology, and is frequently triggered by mutations
in the WNT pathway effector CTNNB1 (b-catenin; Cho et al.,
2011; Ellison et al., 2005; Gajjar et al., 2006; Kool et al., 2008;
Northcott et al., 2011; Thompson et al., 2006). An interesting
distinction between SHH- and WNT-driven MBs is their
anatomic location, with SHH tumors arising laterally in the
cerebellum and WNT MBs arising in the midline close to the
brainstem; recent results indicate that these features reflectressive pediatric brain tumors. This disease is resistant to
ills most affected children within three years of diagnosis.
have advanced understanding of the biology and treatment
ical models of MYC-driven MB has limited understanding of
se model of MB that accurately mimics the transcriptome,
p disease. This model should significantly advance efforts
this deadly childhood cancer.
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et al., 2010).
Modeling both the SHH- and WNT-subgroups of MB in the
mouse (Wu et al., 2011) has been instrumental in providing
insights into the cellular origins of these different disease forms
and paving the way for therapeutic development (Romer et al.,
2004). SHH-subgroup MBs arise within the cerebellum from
committed, SHH-dependent granule neuron precursors (GNPs;
Schu¨ller et al., 2008; Yang et al., 2008). Very recently, we demon-
strated that WNT-subgroup MBs arise outside of the cerebellum
from progenitor cells in the lower rhombic lip (Gibson et al.,
2010). Thus, subgroups of MB are likely to reflect intrinsically
different diseases with distinct origins and driver mutations.
In contrast to the SHH- and WNT-subgroups, very little is
known about the molecular aberrations that drive two other
subgroups of the disease. Non-SHH/WNT tumors include the
most aggressive form of the disease (MYC-subgroup) that
exhibits frequent amplification and/or overexpression of MYC,
portends a dismal prognosis, and generates a high proportion
of aggressive and invasive tumors with large cell/anaplastic
(LC/A) histology (Cho et al., 2011; Ellison et al., 2011a; Northcott
et al., 2011; Pfister et al., 2009).
Mycn is a critical mediator of SHH signals in GNPs (Kenney
et al., 2003) and is absolutely required for normal cerebellar
development; however, much less is known about the function
of Myc in the mouse hindbrain (Knoepfler et al., 2002; Zindy
et al., 2006). Myc is not normally expressed in GNPs (Zindy
et al., 2006), and overexpression of MYC andMYCN is mutually
exclusive and associated with distinct subgroups of humanMBs
(Cho et al., 2011; Northcott et al., 2011). High-level expression
and amplification of MYCN are observed across the various
subgroups of human MB. Aberrant activation of Mycn expres-
sion in the developing mouse cerebellum initiates a variety of
MBs, including both classic and LC/A tumors (Swartling et al.,
2010). In contrast, the highest levels of MYC expression and
MYC amplification are found almost exclusively in the aggressive
MYC-subgroup disease (Cho et al., 2011; Northcott et al., 2011).
Thus, whereas MYCN may play a role in the pathogenesis of
a variety of MBs,MYCmay drive a specific aggressive subgroup
of the disease. This may seem somewhat counterintuitive,
because it is widely thought that the biochemical transcriptional
functions of different MYC-family genes are similar.
Here, we assessed the role of MYC and MYCN in medullo-
blastoma development in the absence of TRP53.
RESULTS
Enforced Expression of Myc but Not Mycn in
Trp53-Deficient Cerebellar Neuronal Progenitors
Induces Aggressive MB
We showed previously that GNP-enriched cell isolates from the
cerebella of postnatal day (P)6–P7 Cdkn2c/, Ptch1+/ or
Cdkn2c/, Trp53/ mice, but not from Cdkn2c/ or wild-
type mice, generate SHH-subgroup MBs when transduced
with a retroviral vector expressing Mycn but not a control virus
(Zindy et al., 2007). To test if Myc might similarly transform
Cdkn2c/, Trp53/ GNPs, we isolated proliferating GNPs
from Cdkn2c/, Trp53/, Atoh1-GFP mice, which are marked
by co-expression of green fluorescent protein (GFP; LumpkinCet al., 2003). Enrichment of GNPs showed that, on average, we
obtained 91.9% of GFP-positive (+) GNPs and 8.1% of GFP-
negative () progenitor cells per preparation and found that the
sorted GFP-expressing population contained 1.1% of GFP-
cells, and, conversely, the GFP- population contained 1.7% of
GFP+ cells. We transduced these cells with viruses either encod-
ing Myc and co-expressing red fluorescent protein (RFP) or
expressing Mycn in lieu of Myc. Fluorescence-activated cell
sorting (FACS) of Myc- and Mycn-transduced cells confirmed
comparable infection efficiencies by the two retroviral vectors
(45.9 ± 11.7% of GFP+/RFP+ for Myc-RFP and 51.6 ± 2.1%
of GFP+/RFP+ for Mycn-RFP). Cells transduced with either
Myc or Mycn (2 3 106 per mouse) were injected separately into
the cerebral cortices of naı¨ve recipient CD-1 nu/nu mice. Myc-
transduced cells formed aggressive tumors that killed mice
significantly faster than GNPs transduced with Mycn (median
survival = 33 days forMyc vs. 48 days forMycn, p < 0.0001, Fig-
ure 1A). Immunoblotting demonstrated significant levels of
ectopic Myc or Mycn protein expression within the two tumor
subsets (Figures S1A and S1B available online). Myc-derived
tumors generated from P6–P7 cerebellar cells of either
Cdkn2c/, Trp53/, or Trp53/ mice occurred with similar
latency (median survival = 39 days for Cdkn2c/, Trp53/ vs.
39 days for Trp53/, p = 0.7096), indicating that the loss of
Cdkn2c was not required for Myc expression to induce MB in
the absence of Trp53 (Figure S1C). Myc-tumors displayed
a consistent morphology that was strikingly similar to human
MBs of the MYC-subgroup (Figure 1B). Morphometric and
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assays of mouse MBs revealed a much larger cell size
and apoptotic rate in Myc-tumors than did mouse models of
the WNT- (Gibson et al., 2010) or SHH-subgroups disease
(Ptch-tumors; Uziel et al., 2005), which typically show a classic
morphology (Figures 1B and 1C). Thus, Myc-induced mouse
MBs resemble the human LC/A MB phenotype reported previ-
ously (McManamy et al., 2003), andMyc andMycn drive distinct
tumors that appear to recapitulate aggressive LC/A and classic
forms of human MB, respectively.
Myc-engineered Murine MBs Have a Distinct
Transcriptome that Mimics Human
MYC-Subgroup Tumors
The decreased latency and LC/A morphology ofMyc-generated
tumors suggested that these were distinct from classic MBs
induced by Mycn. We compared gene expression profiles of
Myc-tumors with those of Mycn-tumors, as well as profiles
generated from previously characterized mouse models of
WNT- and SHH-subgroup MB (Gibson et al., 2010; Uziel et al.,
2005). In addition, we compared these tumor profiles with those
of FACS-sorted Atoh1-GFP-expressing GNPs obtained from the
cerebellum of normal P6 mice lacking both Trp53 and p18Ink4c
protein expression [Cdkn2c/, Trp53/, Atoh1-GFP] mice
(designated GNPs; Figure 2A). The transcriptome of Myc-tumors
was distinct from those of the other mouse MBs (Figure 2A).
Unsupervised hierarchical clustering co-segregated the
gene expression profiles of mouse Mycn-tumors and those of
mouse models of SHH-subgroup disease. In contrast, transcrip-
tomes of Myc-tumors and the mouse WNT-subgroup model
formed two separate clusters. The Mycn/SHH/GNP profilesancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc. 169
Figure 1. MBs Derived from Orthotopic Transplants in the Cortices
of Naive Recipient Mice of Cerebellar Progenitors Overexpressing
Myc and Mycn
(A) Kaplan-Meier survival curves of mice transplanted with cerebellar cells
purified from [Cdkn2c/, Trp53/, Atoh1-GFP] mice infected with Myc-RFP
(red line), Mycn-RFP (blue line), or RFP empty vector (orange line).
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SHH pathway and signature genes of SHH-subgroup MB (Fig-
ure 2B). This observation was confirmed by quantitative RT-
PCR (qRT-PCR), including analysis of Atoh1, Gli1, Sfrp1, and
Boc1 (Figures 2C and 2D). In contrast, Myc and Npr3, which
are specifically expressed in the human MYC-subgroup (North-
cott et al., 2011), were highly expressed in the mouse Myc-
derived MBs (Figure 2B). Immunohistochemical analysis
confirmed that Npr3 is expressed selectively in mouse MYC-
subgroup MBs (Figure S2A). Myc-induced tumors also exhibited
high levels of transcription of Prom1 and Lgr5 (Figure 2B), which
are frequently expressed in stem-cell-like progenitor cells
(Barker et al., 2007; Lee et al., 2005; Zhu et al., 2009). In addition,
high expression of Nanog and Oct4 proteins, considered to be
canonical markers of embryonic pluripotency (Silva and Smith,
2008), was observed in mouse MYC-subgroup and SHH-
subgroup MBs (Figures S2B–S2P). On the other hand, putative
markers of brain tumor stem cells (Rich, 2009) exhibited various
expression levels among the three distinct tumor subgroups
(Figure S2Q).
As a further test of the degree to which mouse Myc-derived
tumors resemble the MYC-subgroup of human MB, we com-
pared the expression of mouse genes with orthologs previously
shown to specifically distinguish the human WNT-, SHH-, and
MYC-subgroup tumors (Cho et al., 2011; Northcott et al., 2011;
Thompson et al., 2006). Thirty-one of 52 orthologs (60%) that ex-
hibited increased expression in the human MYC-subgroup were
similarly upregulated in themouseMyc-tumors (Figure 3A). Forty
of 54 orthologs (74%) with increased expression in the human
WNT-subgroup were similarly increased in the mouse WNT-
tumors (Figure 3B). Thirty-one of 53 orthologs (58%) upregulated
in the human SHH-subgroup were increased in the mouse Ptch-
tumors (Figure 3C). Thus, mouse Myc-induced tumors express
signature genes remarkably similar to those reported for human
MYC-subgroup MB, whereas the mouse Mycn, Ptch, and Trp53
tumors resemble the human SHH-subgroup, and WNT mouse
tumors recapitulate human WNT-subgroup MBs, as reported
previously (Gibson et al., 2010). Furthermore, cross-species
comparison of human and mouse MB transcriptomes (Johnson
et al., 2010) revealed a statistically significant match between
mouse and human MYC-subgroups (Figure S3A). Overall, 56%
of 14,261 ortholog probe pairs showed agreement in gene
expression (upregulation or downregulation) between the human
MYC-subgroup andmouseMyc-tumors (p = 0.009 and p = 0.079
by permutation of the human and mouse data, respectively;(B) Pathology of human and mouse MBs (H&E): (a) a human tumor withMYCN
amplification and classic morphological features, and (b) a human anaplastic
tumor with MYC amplification. Note the difference in nuclear pleomorphism
between classic and anaplastic tumors. The anaplastic tumor also shows
a paving stone-like pattern of cell molding and contains abundant apoptotic
cells, a hallmark of this variant. Mycn-tumors with a classic morphology of
round cells (c, e) contrast with Myc-tumors that show an anaplastic
morphology with cell molding and abundant mitotic figures and apoptotic
bodies (d, f). Scale bar = 50 mm.
(C) Myc-tumor cells are significantly larger and more likely to undergo
apoptosis than are their SHH- and WNT-subgroups counterparts. Error bars
indicate standard deviation. *p < 0.05 for SHH- and WNT-subgroup tumors
compared to the MYC-subgroup. See also Figure S1.
Figure 2. Comparative Molecular Analysis of Engineered Mouse MBs and GNPs
(A) Affymetrix gene chip analysis of mouse Myc- and Mycn-tumors, GNPs purified from the cerebellum of P6 [Cdkn2c/, Trp53/, Atoh1-GFP] mice, from
spontaneous MBs of the SHH-subgroup from [Cdkn2c/, Trp53/, Nestin-cre] and [Cdkn2c/, Ptch1+/] mice and from the mouse WNT-subgroup from
[Ctnnb1+/lox (ex3); Blbp-Cre; Trp53/] mice. Arrowheads indicate Myc-tumors from FACS-sorted GFP-positive (GFP+; green) and GFP-negative (GFP-; red)
cerebellar cells.
(B) Heatmap of differentially regulated genes between Myc- and Mycn-mouse MBs and the SHH-subgroup MBs from the Ptch1+/ and Trp53 null mice, the
WNT-subgroup of tumors, and GNPs.
(C and D) Quantitative RT-PCR (QRT-PCR) analysis of Atoh1, Gli1, Boc, and Sfrp1 (C) andMyc andMycn (D) inMyc-engineered MBs (Myc-1,2,3) compared to
spontaneous Trp53 and Ptch MBs, Mycn-engineered (Mycn-1,2,3) MBs, and GNPs. See also Figure S2.
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Myc-tumors accurately model the transcriptome of human
MYC-subgroup MB.
Probing the Origin of Myc-Engineered MBs
All MBs generated from neuronal progenitors purified from
P7 cerebella of Cdkn2c/, Trp53/, Atoh1-GFP mice and in-
fected with Myc-encoding retroviruses before cortical injection
expressed vector-encoded RFP (Figures 1 and S1D). Mycn
tumors consisted mainly of GFP+/RFP+ cells (70.0 ± 8.20%,
n = 7; Figure S1E). Surprisingly,Myc-induced tumors expressed
little or no GFP (17.2 ± 3.67%, n = 14; Figure S1E), suggesting
that these tumors arise from a small fraction (5%) of GFP- cells
in the GNP-enriched isolates or from GFP+ GNP progenitors thatCsubsequently silence Atoh1-GFP expression during tumor
formation.
To more rigorously characterize the source of mouse MYC-
MBs, we further profiled our cell isolates. Comparison of gene
expression profiles between GFP+, GFP- populations and Myc-
engineered MBs revealed that MYC-subgroup medulloblastoma
most closely matched that of GFP-negative cells (Figure S4A);
however, not all genes, including Lgr5 andNpr3,were expressed
in the GFP-negative sorted cell population (Figure S4B). As a first
step in understanding which cell population might generate
MYC-subgroup MBs, we FACS-sorted GFP-positive and GFP-
negative progenitor cells. These separate fractions were then
transduced with Myc-encoding retroviruses at an efficiency of
30%, and 5 3 104 cells from each transduced fraction wereancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc. 171
Figure 3. Comparison of the Gene Expression Signature of Human MYC-, SHH-, and WNT-Subgroup MB with that of Mouse MBs Reveals
Three Representative Murine Models of the Human Disease
Signature genes that specifically distinguish the human WNT-, SHH-, and MYC-subgroup tumors by their broad subgroup overexpression relative to the others
were compiled from three recent publications on subgroups of MB (Cho et al., 2011; Northcott et al., 2011; Thompson et al., 2006). 52 signature genes relatively
overexpressed by the human MYC-subgroup, 54 by the human WNT-subgroup, and 53 by the human SHH-subgroup were found to have corresponding mouse
orthologs on the Affymetrix 430v2 chip. Shown here are representative heat maps columnswhich compare mean average expression of the orthologs in the three
mouse medulloblastoma models (Myc, Shh, and Wnt). Red indicates a log scale relative increase of expression, whereas green signifies a log scale relative
decrease of expression. The ortholog name and the corresponding first author of the study fromwhich the signature gene was described are listed in the columns
immediately to the right of the heat map.
(A) Thirty-one of 52 orthologs (60%) with increased expression in the human MYC-medulloblastoma subgroup and in the mouse Myc-tumors.
(B) Forty of 54 orthologs (74%) with increased expression in the human WNT-subgroup and in the mouse WNT-tumors.
(C) Thirty-one of 53 orthologs (58%) with increased expression in the human SHH-subgroup and mouse Ptch-tumors. See also Figure S3.
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BothMyc-transduced population generated tumors in the cortex
of naı¨ve recipient animals (Table 1). Histopathological analysis of
tumors revealed that all medulloblastomas derived from GFP+
FACS-sorted cells infected with Myc-encoding viruses (5/8)
showed LC/A characteristics (Table 1 and Figure S4C). In
contrast, tumors occurring after transplants of GFP-negative
cells infected with Myc-expressing retroviruses included two
T-cell lymphomas (2/8), as well as a range of CNS embryonal
tumors—high-grade neuroepithelial tumor with dominant PNET
and focal glial phenotype (3/8) and MBs with LC/A features
(3/8; Table 1). All LC/A MBs expressed low levels of Atoh1
when compared to that of normal GNPs percoll-purified from
the cerebella of P7 wild-type mice (Figure S4D). Comparative
gene expression analysis showed that the MYC-subgroup
MBs derived from Myc-transduced FACS sorted GFP-positive
and GFP-negative cerebellar cell populations had similar
gene profiles as do Myc-tumors derived from unsorted cere-172 Cancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc.bellar cells (Figure 2A). These observations suggest that both
GFP+ and GFP- populations contain cells that can form MYC-
subgroup MBs.
Myc-Engineered MBs Contain Numerous
Tumor-Propagating Cells with High
Proliferative Potential
HumanMYC-typeMBs are the most aggressive of all subgroups
(Cho et al., 2011; Northcott et al., 2011), and consistent with clin-
ical data, mouse Myc-induced tumors developed faster than did
Mycn-MBs (Figure 1A). One possible feature of MYC tumors that
could explain their aggressiveness is that MYC-subgroup MBs
contain a greater fraction of tumor-propagating cells than do
tumors of other subgroups. To estimate the numbers of cells
capable of initiating MBs, cells were purified from mouse MBs
of the SHH- and MYC-subgroups, and different numbers of
tumor cells were injected into the cortices of recipient nude
mice (Figure 4A). Limited dilution experiments revealed that
Table 1. Orthotopic Transplants of FACS sorted Cerebellar Progenitor Cells before Infection with Myc-Encoding Retroviruses
Myc-Infected
FACS-Sorted Population
Transplanted Cells
(Number) Tumor Latency (Days) Phenotype
GFP+ (n = 8) 5 3 104 52, 55, 98, 113, 75 LC/A, MYC-subgroup
GFP (n = 8) 34, 37 T cell lymphoma
5 3 104 51, 53, 69 High-grade neuroepithelial tumor with dominant PNET
and focal glial phenotype
60, 68, 60 LC/A, MYC-subgroup
Neuronal progenitors were purified from the cerebella of postnatal day P7 Cdkn2c/; Trp53/; Atoh1-GFP mice and sorted for GFP-positive and
GFP-negative cell populations. Sorted cells were infected with vectors co-expressing both Myc and RFP, and 5 3 104 cells were transplanted into
the cortices of naı¨ve recipient animals. Data were obtained from three independent experiments. Tumor latency represents the time at which mice
become moribund (median survival = 105.5 days for GFP-positive population and 56.5 days for GFP-negative population). See also Figure S4.
Cancer Cell
MYC-Subgroup of Medulloblastomaequal to more than 2 3 105 purified SHH-subgroup tumor cells
were required for secondary tumor formation (Figure S5), consis-
tent with previous reports (Read et al., 2009). Unlike SHH-
subgroup MB cells, only 1 3 102 Myc-induced tumor cells
were required to generate secondary tumors (5/5; Figure 4A).
Histological analysis confirmed that secondary tumors shared
similar immunohistological characteristics with the parental
primary tumor (Figures 4B–4K).
CD133/Prom1-positive tumor-propagating cells from human
MBs expand in vitro to form ‘‘neurosphere’’ colonies when
plated under conditions that prevent their attachment to the
culture dish (Singh et al., 2004). Given that mouse MYC-
subgroup tumors upregulated Prom1, we tested whether these
tumor cells could similarly form neurospheres. Purified cells
from Myc-tumors were plated on an ultra-low attachment dish
at a density of 53 104 cells/ml in culture medium supplemented
at 3-day intervals with basic fibroblast growth factor (FGF) and
epidermal growth factor (EGF). One week later, spheres were
harvested, dissociated with trypsin, and the total number of
cells per plate was enumerated. Dissociated cells were replated
at the same initial density, cultured under the same conditions,
and sequentially passaged multiple times. Six to seven days
after their first plating, single RFP-positive Myc-derived tumor
cells generated macroscopic red colonies (Figure 5A), the
overall numbers of which had increased more than 20-fold
(Figure 5B, passage 1). Thus, on average, sphere-forming cells
underwent 5–6 population doublings in the first 7-day period.
More cells were recovered at passages 2 and 3, after which
the doubling time of the population slowed down; however,
a consistent proliferative rate approximately equal to 4 popula-
tion doublings in the succeeding 7-day intervals was maintained
from passages 5 to 10 (Figure 5B). In stark contrast, spheres
derived from canonical SHH-subgroup MBs that arose in
Cdkn2c/, Ptch1+/ mice could not be serially passaged at
all under the same culture conditions (Figure S6). Immunohisto-
chemical analysis (Figure 5C) and qRT-PCR (Figure 5D) re-
vealed that neurospheres from Myc-induced MBs expressed
several markers identified in stem/progenitor cells, including
Nanog, Oct4, Sox2, and Lgr5, as well as Nestin and Npr3
(Figure 5C).
To examine whether tumor spheres could be transplanted and
would recapitulate primary Myc-induced MBs, we injected
spheres at passages 2 and 6 into the cortices of recipient
mice. Interestingly, 2 3 105 cells formed tumors with a similar
latency as the secondary MBs generated from cells purifiedCfrom Myc-engineered tumors (7/7, median latency = 22 days;
Figure 6A). Primary and secondary tumors shared the same
pathology and expressed similar immunohistochemical markers
(Figure 6B). Gene profiling of primary and secondary MBs
confirmed that the tumors were distinct from the SHH-subgroup
tumors used as a control (Figure 6C). Thus, tumor spheres reca-
pitulate MYC- subgroup MBs after transplantation.
Myc-Engineered MB Cells Are Resistant to SHH
Signaling Inhibitors
Smoothened inhibitors, including cyclopamine and HhAntag,
inhibit the proliferation and induce the differentiation of SHH-
subgroup MB in vitro and in vivo (Berman et al., 2002; Romer
et al., 2004). Similarly, BMP4 antagonizes SHH signaling,
induces the neuronal differentiation of GNPs (Rios et al.,
2004), extinguishes protein Atoh1 expression, and inhibits the
proliferation of MBs of the SHH-subgroup (Zhao et al., 2008).
Because human MYC-subgroup MBs lack an active SHH
gene expression signature and do not contain activating muta-
tions in SHH pathway genes, we reasoned that mouse MYC-
subgroup tumors might resist smoothened antagonists. Purified
GNPs from cerebella of P7 wild-type mice, from MYC-subgroup
MB, and from a SHH-subgroup MB derived from Cdkn2c/,
Trp53Fl/Fl, Nestin-Cre mice were cultured for 3 days, either in
the presence of cyclopamine, BMP4, or a vehicle control. Cells
were then labeled with BrdU and analyzed by FACS with an anti-
body to BrdU. Cyclopamine or BMP4 reduced the S phase frac-
tion of Cdkn2c/, Trp53Fl/Fl, Nestin-Cre ‘‘primary’’ tumor cells
by 35% to 85% (Figure 7A). In contrast, tumor cells isolated
from 3 independently derived mouse MYC-subgroup tumors
were insensitive to cyclopamine or BMP4 treatment (Fig-
ure 7A), consistent with the finding that MYC-tumors were
associated with low expression of SHH signature genes (Fig-
ure 7B). Similarly, we saw no inhibition of proliferation of neuro-
spheres from MYC-tumors plated in the constant presence of
SHH signaling inhibitors in the culture medium for 2 weeks
(Figure 7C).
DISCUSSION
Enforced expression of Myc, but not Mycn, in concert with the
loss of Trp53 in GNP-enriched mouse cerebellar progenitor cells
gives rise to tumors that recapitulate themost aggressive form of
human MB. These tumors exhibited neither of the characteristic
gene expression signatures previously ascribed to the SHH- orancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc. 173
Figure 4. Mouse MYC-Subgroup MBs before and after Orthotopic
Transplants
(A) Kaplan-Meier survival curve of mice subjected to orthotopic cranial injec-
tion of decreasing number of Myc- primary tumor cells.
(B–K) Sections of tumors were immunostained with H&E (B and G), Ki67,
a marker of proliferating cells (C and H), cleaved Caspase-3, a marker of
apoptosis (D and I), GFAP, thatmarks glial and neural progenitor cells (E and J),
and synaptophysin that characterizes mature neurons (F and K). Scale bar =
50 mm. See also Figure S5.
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MYC-Subgroup of MedulloblastomaWNT-subgroups of the disease (Cho et al., 2011; Northcott et al.,
2011; Thompson et al., 2006). Instead, multitiered analysis of
data comparing the murine tumors with the human MYC-
subgroup revealed convincing similarities in histology, clinical174 Cancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc.behavior, and gene expression between the tumors of both
species.
Marker proteins, including Prom1, Lgr5, Oct4 and Nanog,
found either in embryonic or adult tissue stem cells, as well as
in some ‘‘cancer stem cells,’’ were highly expressed as part of
the defining gene expression signature of Myc-engineered
tumors. Prom1 is a marker of tumor-initiating cells in many
cancers (Curley et al., 2009; Reya et al., 2001; Singh et al.,
2004; Todaro et al., 2010), and Lgr5 is expressed in mitotically
dividing stem cells within the colon and intestinal crypts but
not in their proliferating transient amplifying progeny (Barker
et al., 2007; Zhu et al., 2009). Oct4 and Nanog are considered
markers of pluripotency; although distinct from the ‘‘MYC
expression module’’ (Kim et al., 2010), they can collaborate
with MYC in reprogramming somatic cells to induced pluripotent
stem cells (Takahashi and Yamanaka, 2006). Like those cells
with stem cell characteristics, whose frequencies correlate
with poor prognosis in other cancers (Ben-Porath et al., 2008),
cells from mouse MYC-subgroup MBs could be sequentially
and continuously propagated as cultured neurospheres through
many ex vivo passages. These cells retained tumor-propagating
potential after transplantation into the cortices of recipient mice
and re-induced MBs with the same robust efficiency and
defining cardinal features as the primary MYC-subgroup MBs
from which they were derived. In contrast, tumor cells explanted
from MBs of the SHH-subgroup tend to undergo spontaneous
differentiation in culture, and neurospheres generated from
these tumors rapidly lose their self-renewal capacity when
sequentially passaged (Read et al., 2009; Figure S5). Given
that standard front line therapies fail in children with MYC-
subgroup MBs and such tumors in the mouse are unaffected
by SHH inhibitors now being incorporated into human clinical
trials, the ability to maintain tumor-propagating cells in cultures
from mouse MYC-subgroup MBs may prove useful in establish-
ing a platform for identifying therapeutic drugs.
The generation of an entirely unique subgroup of MB in the
mouse after Myc transduction into Trp53-deficient GNPs (irre-
spective ofCdkn2c loss) was unexpected. In fact, upon embark-
ing on these experiments, a reasonable hypothesis might have
been that ectopically enforced overexpression of Myc would
have had the same effect as overexpression of Mycn, given
that Myc-family proteins bind to the same canonical DNA
consensus sequences (Grandori and Eisenman, 1997) and
interact with similar dimerization partners, co-activators, and
corepressors (Blackwood and Eisenman, 1991; Grandori et al.,
2000). Indeed, despite the fact that Mycn and Myc genes are
differentially expressed in the hindbrain (Zindy et al., 2006) and
that Mycn, but not Myc, is a target of SHH signaling (Kenney
et al., 2003), genetic experiments showed that Mycn can func-
tionally replace Myc in mouse development, proliferation, and
differentiation (Malynn et al., 2000), implying many interchange-
able functions.
The gene expression pattern of the human SHH-subgroup MB
resembles that of GNP cells (Lee et al., 2003) and that of the
WNT-subgroup MB resembles cells derived from the dorsal
brainstem (Gibson et al., 2010), but the gene expression pattern
of the MYC-subgroup of MB, either in mouse or humans, is quite
distinct. This suggests that the latter tumors might arise from
a class of MYC-responsive progenitor cells that differ from those
Figure 5. Myc-Induced Tumor Cells Grow as Neurospheres In Vitro
(A) Tumor cells from mouse MYC-subgroup MBs form red spheres by day 6 after plating. Scale bar = 200 mm.
(B) Spheres can be passaged continuously; here shown up to passage 10 with the cell number increasing up to 25-fold.
(C) Immunostaining of tumor spheres with antibodies against Ki67, Npr3, Nestin, Sox2, Oct4, Nanog, Lgr5, and GFAP. Scale bar = 50 mm.
(D) Spheres share a similar molecular signature (lower levels of SHH signature genes and higher levels of Lgr5 andNpr3) than that of GNPs after several passages
up to passage 10. Data are represented as the mean ± SD. See also Figure S6.
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previous models of mouse MB generated by targeting cerebellar
GNPs invariably yielded tumors of the SHH-subgroup, regard-
less of many different genetic perturbations used to initiate
tumorigenesis (Wu et al., 2011), the more recent derivation of
a WNT-subgroup mouse model stemmed from observations
that a different group of progenitor cells expressed in the dorsal
brain stem, and not cerebellar GNPs, were the most sensitive to
constitutive activation of the WNT signaling pathway (Gibson
et al., 2010). Therefore, one possibility is that target cells most
sensitive to Myc overexpression had contaminated the highly
purified Atoh1-GFP-expressing GNP population into which theCMyc-RFP vector was introduced. Alternatively, enforced Myc
expression in the context of Trp53 loss may have significantly
altered the transcriptional program of GNPs, resulting in their
transdifferentiation, loss of canonical GNP markers, and the
emergence of distinctly different phenotypic features. Either
scenario would account for the observation that RFP-expressing
MYC-subgroup MBs no longer expressed Atoh1-GFP. By
analogy to the strategy for modeling WNT-subgroup MBs
(Gibson et al., 2010), the identification of the cell of origin of
MYC-subgroup tumors will likely require the systematic genera-
tion of genetically engineered animals in whichMyc expression is
conditionally regulated within different cell lineages.ancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc. 175
Figure 6. Tumor Sphere Cells Contain Tumor-
Propagating Cells
(A) Myc-engineered MBs form after transplant of purified
tumor cells or tumor sphere cells at passage 2 (2 3 105
cells) into the cortices of recipient mice.
(B) Comparison of the expression of RFP, GFP, Ki67,
Npr3, Nestin, Sox2, Oct4, Nanog, and Lgr5 by immuno-
histochemistry between primary MB (Primary MB) and
those induced after transplant of spheres (SecondaryMB).
Scale bar = 50 mm.
(C) Comparison of gene signature among Trp53 tumors,
Myc-primary tumors, and Myc-secondary tumors.
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MYC-Subgroup of MedulloblastomaRecent studies have more clearly identified the subgroup of
human MBs that feature highMYC expression and/or amplifica-
tion and carry a dismal prognosis (Cho et al., 2011; Ellison et al.,
2011b; Northcott et al., 2011). Both amplification and overex-
pression ofMYC orMYCN have been associated with poor prog-
nosis in human MB (Pfister et al., 2009). However, in a large
cohort of children studied in the SIOP/PNET3 clinical trial, Ellison
et al. (2011b) recently concluded that amplification of MYC,
rather than MYCN, is associated with the poorest outcome. In
agreement with the latter findings, Myc-induced mouse MBs
were more anaplastic and aggressive than were their Mycn-
induced counterparts, contained a several log-fold higher frac-
tion of tumor-propagating cells, and initiated tumors after
a significantly shorter latency period.
Whereas our finding thatMycn overexpression results in MBs
of the SHH-subgroup seems contradictory to the finding pub-
lished in a recent study by Swartling et al. (2010), which ascribes
Mycn overexpression to the production of a variety of MBs, we176 Cancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc.feel that there are distinctions in the two models
that may explain this discrepancy. The Swar-
tling model links Mycn to a Glt-1 promoter.
Glt-1 is a gene that is not widely expressed by
cells in the external granule layer (EGL) of the
cerebellum, and it is likely that, via Glt-1, Mycn
is influencing a developing cerebellar cell pool
that is distinct from that of the EGL. On the
contrary, in our study Mycn is transfected into
a highly concentrated pool of GNP cells. It
stands to reason that the introduction of
a SHH pathway target member, like Mycn into
GNP/EGL cells, which are particularly sensitive
to SHH stimulated growth, may favor the induc-
tion of SHH-subgroup MB. On the other hand,
MYC—probably because it is not a direct target
of the SHH pathway—appears to have a very
unique and specific effect when transduced
into a similar pool of cerebellar precursor cells.
Mutations of the TP53 gene are found in
human LC/A MBs together withMYC amplifica-
tion (Aldosari et al., 2002; Frank et al., 2004;
Pfister et al., 2009). Although TP53 is frequently
disrupted in LC/A MBs, its loss of function is
observed only infrequently across other
subgroups (Pfaff et al., 2010; Thompson et al.,
2006). Under the conditions used in our mousemodeling experiments, concurrent deregulation of both Myc
and Trp53 was required to induce MYC-subgroup tumors,
whereas neither was effective alone. The genetic interaction
between MYC and TP53 is known to be important in many
different cancers. Whereas Trp53 represses Myc expression
transcriptionally, miss-regulation ofMyc abrogates Trp53-medi-
ated cell cycle arrest through the repression of inhibitors of CDKs
(Hoffman and Liebermann, 2008). Overexpression of Myc also
induces Trp53-dependent apoptosis (Hermeking and Eick,
1994; Wagner et al., 1994), but when accompanied by either
Trp53 mutation or bi-allelic Arf deletion, Myc can readily
generate immortalized tumor cells (Eischen et al., 1999; Hemann
et al., 2005; Zindy et al., 1998).
Sublethal ionizing irradiation of Trp53 null mice at P5–P7 is
sufficient to induce MBs of the SHH-subgroup with very high
penetrance, implying that in this setting, the primary function of
Trp53 is to eliminate rapidly proliferating GNPs that have sus-
tained DNA damage (Uziel et al., 2005). Inactivation of Trp53
Figure 7. Myc-Tumor Cells Are Resistant to SHHSignaling Inhibitors
(A) GNPs purified from the cerebellum from 7-day-old pups and purified tumor
cells were grown in serum-free medium in the absence (Control, black square)
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Csimilarly accelerates MB formation in Ptch1 heterozygous mice,
a context in whichArf deletion has no such effect (Wetmore et al.,
2001). Although Arf is induced by high-signaling thresholds
conveyed by constitutively activated oncogenes, including
Myc (Zindy et al., 1998),Arf is not induced by acute DNA damage
(Kamijo et al., 1997). Moreover, Atoh1-expressing, proliferating
GNPsnormally express relatively high levels of Bmi1, a polycomb
protein suppressor of the Ink4a/Arf locus (Bruggeman et al.,
2005). If the cell of origin of Myc-induced tumors is not an
Atoh1-expressing GNP, this begs the question of whether Arf
null mice, like those lacking Trp53, might be predisposed to
MYC-subgroup MB formation. Conceivably, other mutations in
the Trp53 signaling network might also substitute for inactivation
of Trp53 itself. Next-generation sequencing and comprehensive
analysis of the methylome of primary MYC-subgroup human
MBs should shed light on this issue.
In summary, the generation of a mouse model of MYC-
subgroup MB is of particular importance, because it mimics
the most aggressive subgroup of human MBs that remain the
least responsive to therapy (Ellison et al., 2011b). The model
provides an opportunity to further explore the identity of the
progenitor cells from which these tumors arise and screen for
molecules that may offer improved therapeutic impact.
EXPERIMENTAL PROCEDURES
A detailed description of the Experimental Procedures utilized in this work can
be found in the Supplemental Experimental Procedures (available online).
Mouse Strains and Animal Husbandry
Cdkn2c/, Trp53/, Atoh1-GFP mice were generated by breeding
Cdkn2c/; Trp53/ animals (Uziel et al., 2005) with Atoh1-GFP trans-
genic mice (Lumpkin et al., 2003). Other mice used in this study were
Cdkn2c/; Ptch1+/ (Uziel et al., 2005), Cdkn2c/; Trp53Fl/Fl; Nestin-Cre,
and CTNNB1+/lox (ex3); BLBP-Cre; Trp53Fl/Fl (Gibson et al., 2010). All animal
work was performed under established guidelines and supervision by the St.
Jude Children’s Research Hospital’s Institutional Animal Care and Use
Committee, as required by the United States Animal Welfare Act and the
National Institutes of Health’s policy to ensure proper care and use of labora-
tory animals for research.
GNP Culture, Retrovirus Production, and Infection
Purification of GNPs and other progenitor populations, retrovirus production,
infections, and orthotopic transplants were performed as previously described
(Ayrault et al., 2010). Mouse stem cell virus (MSCV)-based retroviruses encode
the red fluorescent protein (RFP) in cis expressed from an internal ribosomal
entry site. These viruses either express RFP alone or co-express mouse
Myc or Mycn cDNA inserted downstream of the MSCV-LTR. Infection effi-
ciency was analyzed using FACS for RFP and GFP expression. In some exper-
iments, 2 days after plating, infected GNPs were harvested and transplanted
into the cerebella or cortices of CD-1 nu/nu mice (Charles River Laboratories,
Wilmington, MA, USA). In other experiments, GNP-enriched cerebellar cellsor the presence of cyclopamine (light gray square) or BMP4 (dark gray square).
Proliferation was assessed by FACS by calculating the percent of BrdU
positive cells. Proliferation index was defined as the ratio of the percentage of
BrdU-incorporated cells with SHH signaling antagonists to that of control.
(B) GNPs and tumor cells were analyzed by qRT-PCR for specific gene
expression to validate the expression of genes in the SHH signaling pathway.
(C) Treatment of MYC-tumor sphere cells with or without SHH signaling
antagonists under neurosphere culture conditions. Proliferation index repre-
sents the ratio of cell number of cultured neurosphere cells with SHH signaling
antagonists to that of control, 6 and 12 days after plating. Data in graphs A and
C represent the mean ± SD.
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GFP+ and GFP- populations were independently infected with Myc-carrying
retroviruses, and 5 3 104 infected cells from each population were trans-
planted into the cortices of mice 2 days after infection.
Orthotopic Transplants
Transplantation of infected GNP-enriched cerebellar cells into the cortices or
cerebellum of nude recipient mice was performed essentially as described
previously (Ayrault et al., 2010). After transplant of virus-infected progenitor
cells, mice were examined daily for symptoms of sickness (doming of the
head or ataxia or reduced activity). In some instances, purified MB cells or
cultured tumor sphere cells from MYC-tumors were injected back into the
cortices of naı¨ve nu/nu recipient animals.
Tumor Cell Culture and BrdU Analysis
We analyzed progenitors purified from P7 wild-type mice and tumor cells from
three independently derivedMyc-engineered MBs andMBs arising spontane-
ously inCdkn2c/; Trp53Fl/Fl;Nestin-Cremice. Purified GNPs and tumor cells
were plated at 83 105 cells/well on a Matrigel-coated 24-well plate and grown
as previously described (Zhao et al., 2008). GNPs were treated with SHH,
whereas tumor cells were not. Both cell populations were cultured in the pres-
ence or absence of SHH signaling inhibitors, 2.5 mM cyclopamine (LC Labora-
tories, Woburn, MA, USA), or 100 ng/ml BMP4 (R&D Systems). The medium
was changed every 24 hr. Three days after initiation of culture, BrdU was
added to the culture medium at a final concentration of 10 mM, and cells
were harvested 2.5 hr later. Cells that incorporated BrdU were stained with
an anti-BrdU antibody using a BrdU-APC flow kit (BD Bioscience, San Jose,
CA, USA) and analyzed by FACS.
Histopathology, Immunohistochemistry, and Immunoblotting
For histopathology, samples of murine MBs (three separate tumors for each
genotype) were formalin-fixed, paraffin-embedded, and sectioned at 5 mm
thickness. For each sample, a section was stained using a standard hematox-
ylin and eosin (H&E) protocol; a second section was stained for apoptotic cells,
using the ApopTag kit (Millipore, Billerica, MA, USA) with peroxidase detection
of TUNEL labeling. Representative images of each sample/stain combination
were captured (under oil immersion at 403 original magnification) and
analyzed using Axiovision software (Carl Zeiss Microscopy, Thornwood, NY,
USA). A single observer scored each tumor for apoptotic index (percentage
of positive cells following ApopTag labeling) and nuclear area as previously
described (McManamy et al., 2003).
For immunoblotting, purified GNPs from the cerebellum of P7 wild-type
mice or Myc- and Mycn-engineered MB cells were lysed and proteins sub-
jected to immunoblotting as described previously (Zindy et al., 2007).
Procedures and antibodies used for immunohistochemistry and antibodies
for immunoblotting are provided in the Supplemental Experimental
Procedures.
Affymetrix Microarray Analysis
RNA from GNPs or tumor cells were subjected to hybridization using Affyme-
trix Mouse Genechips 430 (version 2; e.g., Figures 2 and 3). For comparative
gene expression analysis between primary and secondary Myc-engineered
tumors, we used Affymetrix Mouse Genechips HT430PM (e.g., Figure 7C).
Microarray results were validated by qRT-PCR using PCR primers shown in
the Supplemental Experimental Procedures.
Neurosphere Assays
Tumor cells were cultured under conditions described previously (Taylor et al.,
2005). Briefly, cells from Myc-engineered tumors were purified and plated on
an ultra-low attachment dish at 53 104 cells/ml or 13 105 cells/well per 6-well
plate. Human recombinant basic FGF and EGF (Peprotech, Rocky Hill, NJ,
USA) were added into the culture medium every 3 days. One week later, tumor
spheres were harvested, pooled, and dissociated with trypsin (Invitrogen,
Grand Island, NY, USA), and total cell numbers were determined. In parallel,
1 3 105 of the dissociated cells were plated again and cultured under the
same conditions. Total RNA was extracted from the reminder of the cultured
cells followed by qRT-PCR analysis of selected RNAs. To test the role of178 Cancer Cell 21, 168–180, February 14, 2012 ª2012 Elsevier Inc.SHH-antagonists, Myc-engineered tumor cells were cultured in the presence
of 2.5 mM cyclopamine or 100 ng/ml BMP4.
ACCESSION NUMBERS
Affymetrix data for mouseMBs using 430V2 and HT430PM chips can be found
in the GenBank database numbers GSE33199 and GSE33200, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.ccr.2011.
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